Citigroup’s Alzamend Neuro ALZN Stock Holding History

Citigroup’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,231	Closed	-$5.54K	–	5702
2026 Q1	$5.54K	Buy	+5,231	New	+$10.4K	﹤0.01%	5236
2025 Q4	–	Sell	-1	Closed	-$2	–	6037
2025 Q3	$2	Buy	+1	New	+$3	﹤0.01%	6015
2025 Q1	–	Sell	-60	Closed	-$631	–	5547
2024 Q4	$631	Buy	+60	New	+$771	﹤0.01%	5619
2022 Q3	–	Sell	-1	Closed	-$2K	–	5790
2022 Q2	$2K	Buy	+1	New	+$1.3K	﹤0.01%	5850

Other funds holding ALZN

KWM

KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Citigroup's ALZN Position: Q2 2026 in Review

Citigroup sold out of Alzamend Neuro (ALZN) in Q2 2026, closing a stake of 5,231 shares — an estimated $5.54K sold.

Citigroup first reported a position in ALZN in Q2 2022 and held it in 4 quarters. The position peaked at $5.54K in Q1 2026. 5 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

Citigroup reported no remaining Alzamend Neuro position as of Q2 2026 after selling out during the quarter.
Citigroup sold 5,231 Alzamend Neuro shares in Q2 2026, an estimated $5.54K.
Citigroup first reported a position in Alzamend Neuro in Q2 2022 and held it in 4 quarters.
Citigroup's Alzamend Neuro position peaked at $5.54K in Q1 2026.
5 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.